4.5 Review

CD44 and HCELL: Preventing hematogenous metastasis at step 1

Journal

FEBS LETTERS
Volume 585, Issue 20, Pages 3148-3158

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.febslet.2011.07.039

Keywords

CD44; Hematopoietic cell E-/L-selectin ligand; Metastasis; Glycosylation; Selectin

Funding

  1. National Institutes of Health
  2. National Heart Lung Blood Institute
  3. National Cancer Institute [PO1 HL107146, RO1 HL60528, RO1 HL73714, RO1 CA121335]

Ask authors/readers for more resources

Despite great strides in our knowledge of the genetic and epigenetic changes underlying malignancy, we have limited information on the molecular basis of metastasis. Over 90% of cancer deaths are caused by spread of tumor cells from a primary site to distant organs and tissues, highlighting the pressing need to define the molecular effectors of cancer metastasis. Mounting evidence suggests that circulating tumor cells (CTCs) home to specific tissues by hijacking the normal leukocyte trafficking mechanisms. Cancer cells characteristically express CD44, and there is increasing evidence that hematopoietic cell E-/L-selectin ligand (HCELL), a sialofucosylated glycoform of CD44, serves as the major selectin ligand on cancer cells, allowing interaction of tumor cells with endothelium, leukocytes, and platelets. Here, we review the structural biology of CD44 and of HCELL, and present current data on the function of these molecules in mediating organ-specific homing/metastasis of CTCs. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available